Israel-based psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) shared additional positive results on the impact of the MEAI molecule in the natural reward process in an in-vivo preclinical study of cocaine addiction.

“We are thrilled to continuously exhibit positive results of our proprietary drug candidate MEAI. The results of these latest in-vivo studies reinforce previous findings and demonstrate that MEAI may be an effective treatment addiction without negatively affecting natural reward," said CEO Dr. Adi Zuloff-Shani. “Cocaine is extremely addictive and there is currently no dedicated treatment. I believe Clearmind is leading the way in this field."

The research, led by …

Full story available on